Dagenais GR, et al. - In patients with dysglycemia, researchers studied the effect of insulin or omega-3 supplements on the incidence and progression of peripheral artery disease (PAD). Study participants with dysglycemia and cardiovascular risk factors were randomly allocated to titrated insulin glargine or standard care, and to either 1 g of omega-3 per day or placebo in the ORIGIN trial. According to results, allocation to insulin glargine vs standard care had a neutral impact on the composite of PAD incidence and progression during a 6.2-year follow-up. Comparable results have been noted for PAD incidence and progression with the allocation of omega-3 vs placebo. Overall, the investigators concluded that the incidence or progression of PAD was not impacted by insulin glargine or omega-3 in this large study.